TIGIT (T cell immunoreceptor with Ig and ITIM domains) also known as VSIG9, VSTM3, and WUCAM, is an immune inhibitory receptor belongs to the poliovirus receptor family of immunoglobulins. It is a prominent immune checkpoint inhibitor expressed on various lymphocytes such as natural killer (NK) cells, effector T cells and regulatory CD4+ T cells. TIGIT binds with high affinity to PVR/CD155 which is expressed on tumor-infiltrating myeloid cells and cancer cells. Upon binding, it suppresses T cell activation, and inhibits T and NK cell cytotoxicity. It is also involved in tumor cell immune evasion, and the inhibition of antiviral immune responses. The ligands for TIGIT also include Nectin-2/CD112 and Nectin-3/CD113. Many tumors evade the immune system response by expressing TIGIT’s ligands and thus inhibiting an anti-cancer immune response and hence, it is considered as an immuno-oncology
Intended Use: IVD
Antibody Type: Monoclonal
Clone: TIGIT/3018
Source: Mouse
Tissue Type: Renal clear cell Carcinoma Tissue